PPARG and metabolic dysfunction-associated steatohepatitis: Another study by Svegliati-Baroni et al. provided further evidence regarding the expression of GLP-1Rs in human hepatocytes and in HepG2 cells, demonstrating that GLP-1R expression was reduced in patients with NASH, while GLP-1R activation reduced the levels of fatty acids in hepatocytes from rats with NASH by 30%, and GLP1-R activation by exenatide inhibited c-Jun N-terminal kinase (JNK) phosphorylation in NASH-hepatocytes, with the effect being peroxisome proliferator-activated receptor (PPARγ)-dependent [37].